KR20210017244A - A composition having a fast-acting sterilizing effect at room temperature - Google Patents

Abstract

The present invention relates to a sterilization composition having an antibacterial effect in an ultra-short time (30 seconds) at room temperature, and a sterilization method using the same, and more particularly, to a sterilizing composition including active ingredients such as capric acid as medium-chain fatty acid and surfactants, a cleaning composition including the composition, a disinfectant composition including the composition, and a method for sterilizing microorganisms at room temperature using the composition. The sterilizing composition of the present invention increases the solubility of the medium chain fatty acid when using the capric acid as medium chain fatty acid and combining a specific surfactant in an appropriate amount, so that bacteria can be effectively sterilized and controlled within 30 seconds even at room temperature (15 to 25°C), so as to be usefully used in pharmaceuticals, food, cosmetics, health care, and medical fields.

Description

Composition having a fast-acting sterilizing effect at room temperature

The present invention relates to a sterilization composition having an antimicrobial effect in a very short time (30 seconds) at room temperature and a sterilization method using the same, and in detail, a sterilization composition comprising capric acid and a surfactant as an active ingredient as a medium-chain fatty acid, the It relates to a detergent composition comprising a composition, a disinfectant composition comprising the composition, and a method of sterilizing microorganisms at room temperature using the composition.

Medium Chain Fatty Acid is a substance that is present in a large amount in the form of neutral fat in milk fat of most animals and oils of plants such as cupea, coconut and palm grown in tropical regions. It has a fatty acid structure without a double bond having 8 to 12 carbon atoms, and includes caprylic acid (C8), capric acid (C10), and lauric acid (C12). Medium-chain fatty acids are often added to livestock feed because they are known to be efficiently digested and absorbed in the digestive system of livestock and have a good effect on the balance of intestinal microbes. In recent years, as it is known to contribute to promoting energy consumption and improving metabolism in the body, it is gaining attention as a functional substance for diet.

Medium-chain fatty acids exhibit excellent antibacterial effects against various pathogens, including intestinal pathogenic microorganisms such as Escherichia coli and Salmonella. However, it has low solubility at room temperature (dissolves 0.0055-0.068 g per 100 ml of water at 20°C), so it is easily eluted in a solid form, so it is limited to be used as an effective antibacterial substance such as surface disinfectant and hand sanitizer, which are generally treated at room temperature. In particular, in the case of capric acid and lauric acid, the Log Po/w (n-octanol/water partition coefficient) value is higher than 4, so it has an excellent ability to permeate and confuse microbial cell membranes. However, there is a limitation in that its efficacy decreases sharply at room temperature.

Currently, medium-chain fatty acids are used in a variety of foods, cosmetics, hygiene products, and quasi-drugs, but they are being combined and used only by relying on the antibacterial activity of the substance itself without understanding the exact concentration conditions and combinations that can optimize the antibacterial activity under specific temperature conditions. to be.

Under this background, the present inventors have tried to find a material that can enhance the antimicrobial effect of medium chain fatty acids in an ultra-short time at room temperature, and when capric acid is used as the medium chain fatty acid and a specific surfactant is combined in an appropriate amount, the solubility of the medium chain fatty acid The present invention was completed by confirming that it can effectively sterilize and control bacteria within 30 seconds even at room temperature.

Korean Patent Publication No. 10-2015-0090559

Accordingly, it is an object of the present invention to provide a sterilizing composition having excellent sterilizing activity within a very short time even at room temperature.

Another object of the present invention is to provide a detergent composition using the composition.

Another object of the present invention is to provide a disinfectant composition using the composition.

Another object of the present invention is to provide a method for sterilizing microorganisms in a very short time even at room temperature by using the composition.

In order to achieve the object of the present invention as described above, the present invention provides a sterilizing composition comprising capric acid and a surfactant as active ingredients.

In one embodiment of the present invention, the surfactant is Polysorbate 20, Polysorbate 80, Sorbitan Monooleate, Cocamidopropyl Betaine And it may be selected from the group consisting of lecithin.

In one embodiment of the present invention, the capric acid may be included in a concentration of 1.0 to 2.5 mM.

In an embodiment of the present invention, the surfactant may be included in an amount of 0.01 to 0.1 v/v%.

In one embodiment of the present invention, the composition is intestinal hemorrhagic Escherichia coli ( Escherichia coli O157:H7, E. coli O157:H7), Salmonella spp., Enterococcus ( Enterococcus) faecalis), Staphylococcus aureus (Staphylococcus aureus), methicillin-resistant Staphylococcus aureus (Methicillin-resistant Staphylococcus aureus, MRSA ), pyogenic streptococci (Streptococcus pyogenes), Listeria monocytogenes (Listeria monocytogenes ), Pseudomonas aeruginosa ) and Serratia marcescens ( Serratia marcescens ) may have bactericidal activity against one or more microorganisms selected from the group consisting of.

In one embodiment of the present invention, the composition may have sterilizing activity at room temperature of 15°C to 25°C.

In addition, the present invention provides a detergent composition comprising the composition.

In addition, the present invention provides a disinfectant composition comprising the composition.

In addition, the present invention provides a microbial sterilization method comprising the step of treating the composition to a sterilization object.

In an embodiment of the present invention, the processing may be performed for 25 to 35 seconds at room temperature of 15°C to 25°C.

The sterilization composition of the present invention effectively sterilizes and controls bacteria within 30 seconds even at room temperature (15℃ ~ 25℃) by enhancing the solubility of medium chain fatty acids when using capric acid as a medium chain fatty acid and combining a specific surfactant in an appropriate amount. As possible, the composition of the present invention can be usefully used in pharmaceuticals, foods, cosmetics, health care, and medical fields.

1 is a variety of microorganisms (Enterococcus pecalis ( Enterococcus ) according to the caprylic acid treatment at room temperature (22 ℃) faecalis), Staphylococcus aureus (Staphylococcus aureus), methicillin-resistant Staphylococcus aureus (Methicillin-resistant Staphylococcus aureus, MRSA ), pyogenic streptococci (Streptococcus pyogenes), is a review, sterilization of the Listeria monocytogenes (Listeria monocytogenes)).
2 is a result of measuring the bactericidal effect on methicillin-resistant Staphylococcus aureus by type (caprylic acid, capric acid, lauric acid) concentration (0.5-2.5 mM) of medium-chain fatty acids at room temperature (22° C.).
3 is a result of measuring the bactericidal effect on methicillin-resistant Staphylococcus aureus by type (caprylic acid, capric acid, lauric acid) concentration (0.5-2.5 mM) of medium-chain fatty acids under medium temperature (37°C) conditions.
Figure 4 is a result of measuring the bactericidal effect on methicillin-resistant Staphylococcus aureus according to the combination of capric acid and various surfactants (Tween 20, Tween 80, Span 80, cocobetaine, and lecithin) at room temperature (22°C) to be.
Figure 5 is a methicillin-resistant Staphylococcus aureus by changing the treatment concentration (0.5-2.5 mM) of capric acid and the treatment concentration (0.01-1.0 v/v%) of Tween 20 as a surfactant at room temperature (22° C.). This is the result of measuring the sterilization effect.
Figure 6 is a methicillin-resistant Staphylococcus aureus by changing the treatment concentration (0.5-2.5 mM) of capric acid and the treatment concentration (0.01-1.0 v/v%) of cocobetaine as a surfactant at room temperature (22°C). This is the result of measuring the sterilization effect.
7 is a photograph of a change in the appearance of an aqueous solution when capric acid alone (Comparative Example 3-6) or Tween 20 or cocobetaine as a surfactant is added to capric acid at 0.01-1.0 v/v%.

The present invention provides a sterilizing composition comprising capric acid, which is a medium-chain fatty acid, and a surfactant as active ingredients.

In general, since medium-chain fatty acids have low solubility at room temperature and are easily eluted in solid form, medium-chain fatty acids having such characteristics have limitations in their use as effective antibacterial substances such as surface disinfectants and hand sanitizers treated at room temperature.

In the present invention, efforts were made to discover a material capable of enhancing the antimicrobial effect of medium chain fatty acids in an ultra-short time at room temperature, and when capric acid is used as the medium chain fatty acid and a surfactant is combined in a specific amount, the solubility of medium chain fatty acids is improved. Thus, it was confirmed through an experiment that bacteria can be effectively sterilized and controlled within 30 seconds even at room temperature.

In the present specification,'Capric Acid' is a saturated fatty acid without a double bond having 10 carbon atoms obtained from fat, and its chemical formula is C ₁₀ H ₂₀ O ₂ , and its solubility in water at room temperature is 0.015 g/100 ml of water. .

In general, the term'room temperature' refers to the average temperature in the outside atmosphere as an average temperature throughout the year, and the temperature range of room temperature defined in the food code is 15°C to 25°C. Therefore, in the present specification, “room temperature” may be defined as a temperature of 15°C to 25°C.

An object of the present invention is to provide a composition having excellent bactericidal activity even at room temperature by using capric acid as a medium chain fatty acid and combining a specific surfactant thereto.

In the present invention, the surfactant is Polysorbate 20, Polysorbate 80, Sorbitan Monooleate, Cocamidopropyl Betaine, and Lecithin ) May be selected from the group consisting of, and preferably polysorbate 20 or cocamidopropyl betaine.

In the present invention, the capric acid may be included in the composition at a concentration of 1.0 to 2.5 mM, and the capric acid may be included in the composition at a concentration of 0.001 to 0.01 v/v%.

In the present invention, the surfactant may be included in a concentration of 0.01 to 0.1 v/v% in the composition, and preferably 0.01 v/v%.

The composition of the present invention is intestinal hemorrhagic Escherichia coli ( Escherichia coli O157:H7, E. coli O157:H7), Salmonella spp., Enterococcus ( Enterococcus) faecalis), Staphylococcus aureus (Staphylococcus aureus), methicillin-resistant Staphylococcus aureus (Methicillin-resistant Staphylococcus aureus, MRSA ), pyogenic streptococci (Streptococcus pyogenes), Listeria monocytogenes (Listeria monocytogenes ), Pseudomonas aeruginosa ) and Serratia marcescens ( Serratia marcescens ) may have bactericidal activity against one or more microorganisms selected from the group consisting of.

In general, the cell membrane of Gram-positive bacteria is thicker than Gram-negative bacteria by a layer of peptidoglycan, and in particular, methicillin-resistant Staphylococcus aureus ( hereinafter abbreviated as'MRSA' for short) has a mechanism of antibiotic resistance. Because it has, it is recognized as a strain with strong resistance compared to other strains. On the other hand, according to a conventional study, it is known that the resistance of MRSA is significantly higher when treated with caprylic acid under the same conditions as compared to other strains, and thus, the bacterial reducing activity is low when treated with an antimicrobial substance (see FIG. 1). Therefore, it is obvious in the art that it is judged to have bactericidal activity against other bacteria when it has bactericidal activity against MRSA, which is more resistant than other strains.

In the following examples of the present invention, three strains of methicillin-resistant Staphylococcus aureus (MRSA) were tested (ATCC 33591, 33592, 43300) in order to evaluate the bactericidal activity of a composition containing capric acid and a surfactant as an active ingredient. It was used in, and it was demonstrated through an experiment that remarkably excellent bactericidal activity within a very short time (30 seconds) at room temperature according to the combination of the above ingredients.

Therefore, the composition of the present invention comprising capric acid and a surfactant as an active ingredient has bactericidal activity against various bacteria including methicillin-resistant Staphylococcus aureus.

The composition of the present invention is characterized by having a bactericidal activity at room temperature of 15°C to 25°C by including capric acid and a surfactant as active ingredients.

In addition, the present invention provides a detergent composition comprising the composition (a sterilizing composition comprising capric acid and a surfactant as an active ingredient).

In the present invention, the term “sterilization” means killing microorganisms such as bacteria, yeast, and mold.

The detergent composition of the present invention may exemplify a hand cleaner, a body cleaner, a liquid shampoo, a liquid rinse, a liquid soap, a feminine cleaner, and the like, but the type is not particularly limited.

As long as the'hand sanitizer' includes a sterilizing composition comprising the above-described medium-chain fatty acid, capric acid and a surfactant, as active ingredients, a manufacturing method and a material for a conventional hand sanitizer may be used.

For example, the hand sanitizer may contain glycerin as a humectant. The humectants present in hand sanitizers can be advantageously placed on the skin when the detergent is used, helping to sustain the lipids and essential oils present in the skin. Specific examples of suitable humectants include glycerin, glycerin derivatives, sodium hyaluronate, hyaluronic acid, betaine, amino acids, glycosaminoglycans, honey, sorbitol, propylene. Glycols such as glycols, polyols, sugars, hydrogenated starch hydrolysate, PCA salts such as sodium PCT, lactic acid, lactate, urea, and the like.

In addition, the hand sanitizer may include an emollient. Suitable emollients are petroleum-based oils, petrolatum, vegetable oils, mineral oils, natural or synthetic oils, lanolin and its derivatives, fatty esters, glycerol esters and derivatives, propylene glycol esters and derivatives, alkoxylated carboxylic acids. , Alkoxylated alcohols, fatty alcohols, fatty acids and mixtures thereof.

Suitable esters may include, but are not limited to, cetyl palmitate, stearyl palmitate, cetyl stearate, isopropyl laurate, isopropyl myristate, isopropyl palmitate, and mixtures thereof. Fatty alcohols may include, but are not limited to, octyldodecanol, lauryl, myristyl, cetyl, stearyl, behenyl alcohol, and mixtures thereof. Ethers such as eucalyptol, ceteraryl glucoside, dimethylisosorbic polyglyceryl-3 cetyl ether, polyglyceryl-3 decyltetradecanol, propylene glycol myristyl ether, and mixtures thereof are also suitably emollients. Can be used.

Suitable natural fats or oils include fats, oils, essential oils, essential fatty acids, non-essential fatty acids, phospholipids and mixtures thereof. These natural fats and oils can provide a source of essential and non-essential fatty acids found in the skin's natural barriers. Particular examples of suitable natural fats or oils are citrus oil, olive oil, avocado oil, apricot oil, babassu oil, camellia oil, canola oil. , Castor oil, coconut oil, corn oil, cottonseed oil, emu oil, evening primrose oil, hydrogenated cottonseed oil, hydrogenated palm kernel oil, malated Maleated soybean oil, meadowfoam oil, palm kernel oil, peanut oil, rapeseed oil, grapeseed oil, safflower oil, sphingolipids, flaxseed Seed almond oil, tall oil, lauric acid, palmitic acid, stearic acid, linoleic acid, stearyl alcohol, Lauryl alcohol, myristyl alcohol, behenyl alcohol, rose hip oil, calendula oil, chamomile oil, eucalyptus oil ( eucalyptus oil), juniper oil, sandlewood oil, tea tree oil, sunflower oil, soybean oil, thyme oil, and their It may contain mixtures.

In addition, the present invention provides a disinfectant composition comprising the composition (a sterilizing composition comprising capric acid and a surfactant as an active ingredient).

The disinfectant composition of the present invention may exemplify a hand disinfectant, a human disinfectant, a ward disinfectant, an animal disinfectant, and the like, but the type is not particularly limited.

The general hand sanitizer currently on the market uses one of ethanol, isopropanol, benzalkonium chloride, cresol, and hydrogen peroxide as the main component, and a gel form containing alcohol in an amount of 60 to 70% is a water-free hand sanitizer. Most common. As such hand sanitizers use synthetic chemicals such as ethanol, isopropanol, benzalkonium chloride, cresol or hydrogen peroxide, which are used as main raw materials, skin diseases such as allergies and skin troubles have been problematic.

However, the disinfectant composition of the present invention can effectively sterilize and control bacteria within 30 seconds even at room temperature by enhancing the solubility of the medium chain fatty acid when capric acid is used as the medium chain fatty acid and a specific surfactant is combined in an appropriate amount. Compared to the disinfectant that is used, it is harmless and safe to the human body.

The disinfectant composition of the present invention may be fragrance-free, and a natural fragrance may be added to impart a fragrance.

Examples of the natural fragrance include rosemary, lavender, rose, labandin, lemon, rosewood, mandarin, jasmine, and basil. ), sandalwood, bergamot, citronella, orange, eucalyptus, chamomile, palmarosa (palmarosa) or marjoram (natural) obtained from plants such as Extracts or essential oils can be used.

In addition, the disinfectant composition of the present invention may further include a natural thickener. Natural thickeners are added for the safety of bubbles that may occur in the composition.For example, natural polymers such as starch, xanthan gum, locust bean gum, carrageenan, pectin gelatin, and other thickeners of natural materials may be mixed. , It may be mixed in an amount of 0.0001 to 10% by weight based on the total weight of the prepared disinfectant composition.

In addition, the disinfectant composition of the present invention can be prepared by varying the pH according to the use, and to adjust the pH, a natural pH control substance such as grape seed extract, lemon juice, vinegar, malic acid, or the like is used or citric acid is used to adjust the pH. Can be lowered, it can be configured to increase the pH using potassium hydroxide or sodium hydroxide.

Meanwhile, the disinfectant composition according to the present invention as described above may be prepared by formulating in a liquid, gel, emulsion, or aerosol form, but the formulation is not particularly limited.

The problem of disinfecting wards in hospitals treating patients with diseases caused by pathogenic bacteria and disinfecting hands, human bodies, clothes and medical devices of medical workers is not simple. In general, a strong acid, strong base, or chlorine-based disinfectant is used to disinfect the disinfectant composition of the present invention, and the disinfectant composition of the present invention prevents methicillin-resistant Staphylococcus aureus, which has stronger resistance than other strains, at room temperature (15-25°C) for an ultra-short time (30 seconds) Effectively kills the bar, it can be actually usefully used in the medical field.

In addition, the disinfectant composition according to the present invention enables animal disinfection, livestock disinfection, and direct disinfection of livestock farmers and farmers.

In addition, the present invention provides a sterilization method comprising the step of treating the composition (a sterilization composition comprising a medium-chain fatty acid, capric acid and a surfactant as an active ingredient) on a sterilization target.

The step of treating the composition to the sterilization target may be performed for 25 to 35 seconds at room temperature of 15° C. to 25° C., and can be easily and quickly performed without conditions such as high temperature or high pressure.

Hereinafter, the present invention will be described in more detail through examples. These examples are for explaining the present invention more specifically, and the scope of the present invention is not limited to these examples.

<Example 1>

Preparation of an experiment to verify the sterilization effect of the composition of the present invention

<1-1> Strain and culture used

Methicillin-resistant Staphylococcus aureus ( MRSA) , which is a widespread problem in food, healthcare, and medical fields due to the fact that the control of Gram-positive bacteria is very difficult compared to Gram-negative bacteria due to its thick cell membrane structure 3 Dog strains (ATCC 33591, 33592, 43300) were used in the experiment. Each strain was inoculated with 30 μl in 3 ml of Mueller Hinton broth (BD Difco) and incubated for 24 hours at 37°C. After washing with 0.85% sterile physiological saline, a cocktail of three strains was prepared and used. .

For reference, in a previous study, the present inventors found that the resistance of methicillin-resistant Staphylococcus aureus (MRSA) was significantly higher than that of other strains when caprylic acid was treated under the same conditions, and the resulting caprylic acid treatment had the lowest bacterial reducing activity. Confirmed (see Fig. 1). Therefore, it was judged that the bactericidal activity against other bacteria would be high when the bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA), which is more resistant than other strains, was determined to be high. Cylin resistant Staphylococcus aureus (MRSA) was used.

<1-2> Preparation of medium chain fatty acid standard solution

Caprylic acid (Sigma Aldrich, Korea), capric acid (Sigma Aldrich, Korea), and lauric acid (Sigma Aldrich, Korea) were used as the medium-chain fatty acids. Caprylic acid, capric acid, and lauric acid used in the experiment were dissolved in 99.9% ethanol, and a 1.0 M stock solution was diluted in ethanol to obtain 50-250 mM of concentrated fatty acid, and the prepared aqueous solution was diluted with sterilized distilled water. Thus, a standard solution was prepared so that the final concentration was 0.5-2.5 mM.

<1-3> Preparation of surfactant standard solution

Tween 20 (Sigma Aldrich, Korea), Tween 80 (Sigma Aldrich, Korea), Span 80 (Sigma Aldrich, Korea), cocobetaine (Sigma Aldrich, Korea) and lecithin (Serva, Heidelberg, Germany) were used as surfactants. I did. Each of the surfactants used in the experiment was diluted 100 times in sterilized distilled water using a 1-100% stock solution prepared using sterilized distilled water as a solvent to prepare a standard solution so that the final concentration was 0.01-1.0 v/v%. I did.

<Experimental Example 1>

Comparison of sterilizing power of medium-chain fatty acids at room temperature (22℃) and medium temperature (37℃)

In this experiment, in order to evaluate the sterilizing power of each type of medium-chain fatty acid at room temperature (22°C) and medium temperature (37°C), the type of medium-chain fatty acid (caprylic acid, capric acid, lauric acid) and treatment concentration (0.5- 2.5 mM) and treatment temperature (22° C., 37° C.) were changed to measure the bactericidal effect on methicillin-resistant Staphylococcus aureus. In Table 1 below, Examples 1-24 are shown in detail.

For the evaluation of sterilization ability, 100 μl of the previously prepared strain mixture was inoculated into the medium chain fatty acid alone treatment group to maintain a total volume of 10 ml. The untreated group (control group) and the treated group without treatment with antibacterial substances were exposed to 22℃ or 37℃ for 30 seconds in a constant temperature water bath and treated with a neutralizing D/E buffer. After 10 dilution in sterile physiological saline, Mueller 100 μl was dispensed into Hinton agar (BD Difco) and spread. In order to lower the detection limit, 1 ml of the stock solution immediately after treatment was directly dispensed onto four plates and plated immediately. All media were cultured at 37° C. for 24 hours, and colonies were counted. The bacterial reduction was calculated by subtracting the number of bacteria after treatment from the initial number of bacteria (log CFU/ml). All experiments were performed in 4 iterations.

Examples 1 to 24 Example Medium chain fatty acid Treatment concentration (mM) Treatment temperature (℃) Processing time (seconds) Example 1 Caprylic acid 0.5 22 30 Example 2 Caprylic acid 1.0 22 30 Example 3 Caprylic acid 1.5 22 30 Example 4 Caprylic acid 2.5 22 30 Example 5 Capric acid 0.5 22 30 Example 6 Capric acid 1.0 22 30 Example 7 Capric acid 1.5 22 30 Example 8 Capric acid 2.5 22 30 Example 9 Lauric acid 0.5 22 30 Example 10 Lauric acid 1.0 22 30 Example 11 Lauric acid 1.5 22 30 Example 12 Lauric acid 2.5 22 30 Example 13 Caprylic acid 0.5 37 30 Example 14 Caprylic acid 1.0 37 30 Example 15 Caprylic acid 1.5 37 30 Example 16 Caprylic acid 2.5 37 30 Example 17 Capric acid 0.5 37 30 Example 18 Capric acid 1.0 37 30 Example 19 Capric acid 1.5 37 30 Example 20 Capric acid 2.5 37 30 Example 21 Lauric acid 0.5 37 30 Example 22 Lauric acid 1.0 37 30 Example 23 Lauric acid 1.5 37 30 Example 24 Lauric acid 2.5 37 30

Converting the molar concentration of medium chain fatty acid to% concentration Medium chain fatty acid 0.5 mM 1.0 mM 1.5 mM 2.5 mM Caprylic acid 0.008 v/v% 0.016 v/v% 0.024 v/v% 0.040 v/v% Capric acid 0.010 v/v% 0.020 v/v% 0.030 v/v% 0.049 v/v% Lauric acid 0.012 v/v% 0.023 v/v% 0.035 v/v% 0.058 v/v%

As a result, as shown in Table 3 and Fig. 2-3 below, caprylic acid (Example 1-4) and lauric acid (Example 9-12) alone treatment at room temperature (22° C.) Example 5-8) In the case of single treatment, it was confirmed that the reduction effect on methicillin-resistant Staphylococcus aureus was remarkably excellent, and in particular, the treatment with 1.5 mM capric acid (Example 7) showed a maximum reduction effect of 4.1 log. On the other hand, when the treatment temperature of the medium-chain fatty acids was increased to 37°C, the antimicrobial efficacy of all medium-chain fatty acids was increased compared to the room temperature treatment, and in particular, the The methicillin-resistant Staphylococcus aureus reduction effect was markedly over 5 log.

Comparison of sterilization power of medium chain fatty acids at room temperature (22℃) and medium temperature (37℃) Room temperature (22℃) Average Standard Deviation Medium temperature (37℃) Average Standard Deviation Example 1 -0.0312 0.0279 Example 13 -0.0215 0.0809 Example 2 0.0186 0.0927 Example 14 0.0367 0.2950 Example 3 0.3103 0.2561 Example 15 0.5065 0.0834 Example 4 0.3887 0.0912 Example 16 2.0986 1.8385 Example 5 2.9776 0.5671 Example 17 6.6295 0.2213 Example 6 3.9584 0.6558 Example 18 6.7602 0.1228 Example 7 4.0814 1.0828 Example 19 6.7602 0.1228 Example 8 3.4381 1.3718 Example 20 6.7602 0.1228 Example 9 0.1978 0.3547 Example 21 5.4118 0.1788 Example 10 1.4984 0.3099 Example 22 5.5708 0.3093 Example 11 1.6432 0.4976 Example 23 5.9558 0.8262 Example 12 1.4534 0.1330 Example 24 5.7328 1.1428

<Experimental Example 2>

Comparison of sterilizing power of medium chain fatty acid and surfactant combination

In this experiment, in order to evaluate the bactericidal power according to various combinations of medium-chain fatty acids and surfactants at room temperature (22°C), the types of medium-chain fatty acids (capric acid, lauric acid) and the types of surfactants (Tween 20, Tween 80, Span 80, cocobetain, lecithin) was changed to measure the bactericidal effect against methicillin-resistant Staphylococcus aureus. The group treated with capric acid alone was used as Comparative Example 1, and the group treated with lauric acid alone was used as Comparative Example 2. In Table 4 below, Comparative Examples and Examples 25-34 are shown in detail.

To evaluate the sterilization ability, 100 μl of the previously prepared strain mixture was inoculated into the treatment group in which the medium-chain fatty acid and surfactant were mixed to maintain a total volume of 10 ml. The untreated group (control group) and the treated group without treatment with antibacterial substances were exposed to 22℃ or 37℃ for 30 seconds in a constant temperature water bath and treated with a neutralizing D/E buffer. After 10 dilution in sterile physiological saline, Mueller 100 μl was dispensed into Hinton agar (BD Difco) and spread. In order to lower the detection limit, 1 ml of the stock solution immediately after treatment was directly dispensed onto four plates and plated immediately. All media were cultured at 37° C. for 24 hours, and colonies were counted. The bacterial reduction was calculated by subtracting the number of bacteria after treatment from the initial number of bacteria (log CFU/ml). All experiments were performed in 4 iterations.

Examples 25 to 34 Example Medium chain fatty acid Treatment concentration
(mM) Surfactants Treatment concentration
(v/v%) Treatment temperature
(℃) Processing time
(second) Comparative Example 1 Capric acid 1.5 - - 22 30 Example 25 Capric acid 1.5 Tween 20 0.01 22 30 Example 26 Capric acid 1.5 Tween 80 0.01 22 30 Example 27 Capric acid 1.5 Span 80 0.01 22 30 Example 28 Capric acid 1.5 Coco-betaine 0.01 22 30 Example 29 Capric acid 1.5 Lecithin 0.01 22 30 Comparative Example 2 Lauric acid 1.5 - - 22 30 Example 30 Lauric acid 1.5 Tween 20 0.01 22 30 Example 31 Lauric acid 1.5 Tween 80 0.01 22 30 Example 32 Lauric acid 1.5 Span 80 0.01 22 30 Example 33 Lauric acid 1.5 Coco-betaine 0.01 22 30 Example 34 Lauric acid 1.5 Lecithin 0.01 22 30

As a result, as shown in Table 5 and FIG. 4, when treatment at room temperature by combining 0.01 v/v% of a surfactant with 1.5 mM capric acid (Examples 25-29), compared to Comparative Example 1, Example 25 , It was confirmed that the methicillin-resistant Staphylococcus aureus reduction effect of Examples 28 and 29 was significantly increased. In particular, when Tween 20 (Example 25) or cocobetaine (Example 28) was combined with capric acid as a surfactant, it showed a bactericidal effect of 2 log or more. On the other hand, in the case of lauric acid, the solubility in water at room temperature is significantly lower than that of capric acid, and even if 0.01 v/v% of a surfactant is added (Examples 30-34), it was found that the sterilizing power did not increase compared to Comparative Example 2. .

Comparison of disinfecting power of aqueous solution of capric or lauric acid and surfactant combination Capric acid Average Standard Deviation Lauric acid Average Standard Deviation Comparative Example 1 4.0814 1.0828 Comparative Example 2 1.1125 0.9007 Example 25 6.6714 0.3670 Example 30 0.2443 0.2961 Example 26 4.2902 0.9466 Example 31 0.4310 0.5943 Example 27 1.7549 1.1248 Example 32 0.2007 0.2452 Example 28 6.8721 0.0361 Example 33 0.4909 0.3423 Example 29 6.1127 1.0445 Example 34 0.0534 0.0926

<Experimental Example 3>

Comparison of sterilizing power and appearance change of capric acid and surfactant combination

<3-1> Evaluation of sterilization power

In this experiment, in order to evaluate the sterilization power according to various combinations of capric acid and various concentrations of surfactants at room temperature (22℃), the treatment concentration of capric acid (0.5-2.5 mM), the type of surfactant (twin 20, Cocobetain) and the treatment concentration (0.01-1.0 v/v%) of the surfactant were changed to measure the bactericidal effect against methicillin-resistant Staphylococcus aureus. The group treated with capric acid alone was used as a comparative example. In Table 6 below, Comparative Examples 3-6 and 35-58 are shown in detail.

Evaluation of sterilization power was evaluated in the same manner as in <Example 3>.

Examples 35-58 Example Medium chain fatty acid Treatment concentration
(mM) Surfactants Treatment concentration
(v/v%) Treatment temperature
(℃) Processing time
(second) Comparative Example 3 Capric acid 0.5 - - 22 30 Comparative Example 4 Capric acid 1.0 - - 22 30 Comparative Example 5 Capric acid 1.5 - - 22 30 6 in comparison Capric acid 2.5 - - 22 30 Example 35 Capric acid 0.5 Tween 20 0.01 22 30 Example 36 Capric acid 0.5 Tween 20 0.1 22 30 Example 37 Capric acid 0.5 Tween 20 1.0 22 30 Example 38 Capric acid 1.0 Tween 20 0.01 22 30 Example 39 Capric acid 1.0 Tween 20 0.1 22 30 Example 40 Capric acid 1.0 Tween 20 1.0 22 30 Example 41 Capric acid 1.5 Tween 20 0.01 22 30 Example 42 Capric acid 1.5 Tween 20 0.1 22 30 Example 43 Capric acid 1.5 Tween 20 1.0 22 30 Example 44 Capric acid 2.5 Tween 20 0.01 22 30 Example 45 Capric acid 2.5 Tween 20 0.1 22 30 Example 46 Capric acid 2.5 Tween 20 1.0 22 30 Example 47 Capric acid 0.5 Coco-betaine 0.01 22 30 Example 48 Capric acid 0.5 Coco-betaine 0.1 22 30 Example 49 Capric acid 0.5 Coco-betaine 1.0 22 30 Example 50 Capric acid 1.0 Coco-betaine 0.01 22 30 Example 51 Capric acid 1.0 Coco-betaine 0.1 22 30 Example 52 Capric acid 1.0 Coco-betaine 1.0 22 30 Example 53 Capric acid 1.5 Coco-betaine 0.01 22 30 Example 54 Capric acid 1.5 Coco-betaine 0.1 22 30 Example 55 Capric acid 1.5 Coco-betaine 1.0 22 30 Example 56 Capric acid 2.5 Coco-betaine 0.01 22 30 Example 57 Capric acid 2.5 Coco-betaine 0.1 22 30 Example 58 Capric acid 2.5 Coco-betaine 1.0 22 30

As a result, as shown in Table 7 and FIG. 5, when Tween 20 was added at 0.01 v/v%, the reduction effect of Examples 38, 41, and 44 was 5 log or more compared to Comparative Example 4-6. It can be seen that it is significantly increased, and in particular, when 0.01 v/v% of Tween 20 was added to 1.5 mM of capric acid, it was confirmed that the methicillin-resistant Staphylococcus aureus was killed at a level of 6.3 log. On the other hand, when the concentration of Tween 20 was increased to 0.1 v/v% or more, antagonism with capric acid was exhibited. For example, when 0.1% of Tween 20 was added to 2.5 mM capric acid (Example 45), 0.01 v/v It was confirmed that the reduction effect was reduced by 4 log or more compared to the case where v% of Tween 20 was added (Example 44).

In addition, as shown in Table 7 and FIG. 6, it can be seen that in the case of coco-betaine, the reduction effect of Examples 53 and 56 is significantly increased to 5 log or more compared to Comparative Example 5-6. In particular, when 0.01 v/v% of cocobetaine was added to 1.5 mM of capric acid, it was confirmed that the methicillin-resistant Staphylococcus aureus was killed at a level of 6.9 log. On the other hand, when cocobetaine was combined with 0.1 v/v% or more in capric acid 1.5 mM or more, antagonism was exhibited.For example, 0.1 v/v% cocobetaine was added to 2.5 mM capric acid (Example 57) It was confirmed that the reduction effect was reduced by 5 log or more compared to the case of adding 0.01 v/v% of coco betaine (Example 57).

Comparison of disinfecting power of aqueous capric acid solution and surfactant combination Tween 20 Average Standard Deviation Coco-betaine Average Standard Deviation Comparative Example 3 1.5249 1.5812 Comparative Example 3 1.5249 1.5812 Example 35 1.2370 1.8613 Example 47 0.6656 0.3307 Example 36 0.1993 0.1269 Example 48 2.1091 0.2663 Example 37 0.1978 0.2959 Example 49 1.2022 0.9216 Comparative Example 4 2.9158 0.9225 Comparative Example 4 2.9158 0.9225 Example 38 5.5888 0.9306 Example 50 2.0422 0.2663 Example 39 0.4021 0.3881 Example 51 2.0743 0.2663 Example 40 0.0753 0.1105 Example 52 1.2027 0.7666 Comparative Example 5 3.6714 0.3855 Comparative Example 5 3.6714 0.3855 Example 41 6.2834 1.0382 Example 53 6.8721 0.0361 Example 42 0.3850 0.2344 Example 54 0.9101 0.4408 Example 43 0.1317 0.3804 Example 55 0.5876 0.0915 Comparative Example 6 2.6927 0.4048 Comparative Example 6 2.6927 0.4048 Example 44 5.3084 1.1299 Example 56 5.4330 0.2986 Example 45 1.1392 1.2328 Example 57 0.2340 0.2663 Example 46 0.0775 0.2483 Example 58 0.7785 0.1125

<3-2> Comparison of appearance change

When capric acid was treated alone (Comparative Example 3-6) or a surfactant was added to capric acid in an amount of 0.01-1.0 v/v% (Examples 35-58), the appearance change of the aqueous solution was examined.

As a result, as shown in FIG. 7, it was confirmed that white capric acid crystals were observed at 1.0 mM or more when capric acid was treated alone, and the amount of crystals increased as the concentration increased. When 0.01 v/v% of Tween 20 or cocobetaine is added to 2.5 mM of capric acid, it can be seen that the aqueous solution becomes more turbid compared to the case without addition, which means that a trace amount of capric acid in a crystallized state is This is because it exists in an aqueous solution in a state dispersed by a surfactant. When the amount of surfactant is added in an amount of 0.1 v/v% or more, it can be confirmed that capric acid is more dissolved in the aqueous solution at room temperature and the aqueous solution becomes clear. This is because the surfactant forms a micelle structure and surrounds capric acid. As a result, the solubility increases but the antibacterial activity decreases.

So far, the present invention has been looked at around its preferred embodiments. Those of ordinary skill in the art to which the present invention pertains will be able to understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative point of view rather than a limiting point of view. The scope of the present invention is shown in the claims rather than the foregoing description, and all differences within the scope equivalent thereto should be construed as being included in the present invention.

Claims (10)

A sterilizing composition comprising capric acid and a surfactant as an active ingredient. The method of claim 1,
The surfactant is from the group consisting of Polysorbate 20, Polysorbate 80, Sorbitan Monooleate, Cocamidopropyl Betaine, and Lecithin. A composition characterized in that it is selected. The method of claim 1,
The composition, characterized in that the capric acid is contained in a concentration of 1.0 to 2.5 mM. The method of claim 1,
The composition, characterized in that the surfactant is contained in an amount of 0.01 to 0.1 v/v%. The method of claim 1,
The composition is intestinal hemorrhagic Escherichia coli ( Escherichia coli O157:H7, E. coli O157:H7), Salmonella spp., Enterococcus ( Enterococcus) faecalis), Staphylococcus aureus (Staphylococcus aureus), methicillin-resistant Staphylococcus aureus (Methicillin-resistant Staphylococcus aureus, MRSA ), pyogenic streptococci (Streptococcus pyogenes), Listeria monocytogenes (Listeria monocytogenes ), Pseudomonas aeruginosa ), and Serratia marcescens ( Serratia marcescens ), characterized in that it has a bactericidal activity against at least one microorganism selected from the group consisting of. The method of claim 1,
The composition is a composition characterized in that it has a bactericidal activity at room temperature of 15 ℃ ~ 25 ℃. A cleaning composition comprising the composition of any one of claims 1 to 6. A disinfectant composition comprising the composition of any one of claims 1 to 6. A sterilization method comprising the step of treating the composition of any one of claims 1 to 6 to a sterilization object. The method of claim 9,
The treating step is a sterilization method, characterized in that made for 25 to 35 seconds at room temperature of 15 ℃ ~ 25 ℃.

Images